ArticleCureus2026
Central Diabetes Insipidus as a Rare Presentation of Small Cell Lung Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung carcinoma (SCLC) is an aggressive neuroendocrine malignancy commonly associated with paraneoplastic syndromes, most often the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Central diabetes insipidus (CDI) is a rare manifestation and may result from hypothalamic-pituitary involvement by metastatic disease. A 53-year-old man with a significant smoking history presented with abdominal pain and was found to have a right perihilar lung mass with extensive metastatic disease. Liver biopsy confirmed SCLC. During hospitalization, he developed acute polyuria with worsening hypernatremia, elevated serum osmolality, and inappropriately dilute urine. A marked concentrating response following desmopressin administration supported the diagnosis of CDI, while MRI of the brain demonstrated a sellar-suprasellar mass with laboratory findings concerning for central hypothyroidism, indicating hypothalamic-pituitary axis disruption. Given the rapid onset of symptoms and widespread metastatic disease, pituitary metastasis was considered the most likely etiology. Despite initiation of desmopressin and systemic chemotherapy, the patient experienced progressive clinical decline and ultimately transitioned to comfort care. This case highlights a rare presentation of SCLC with CDI likely due to pituitary metastasis. New-onset polyuria and hypernatremia in patients with advanced malignancy should prompt evaluation for CDI to allow timely diagnosis and management, even in the setting of poor overall prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.